Survival analysis of gastric cancer patients with tumor thrombus in the portal vein

Background A tumor thrombus in the portal vein originating from gastric cancer is a rare condition. Little is known about the development of portal vein tumor thrombus (PVTT) and its effect on the survival of gastric cancer patients. Methods PVTT originating from gastric cancer was identified retros...

Full description

Saved in:
Bibliographic Details
Published inJournal of surgical oncology Vol. 105; no. 3; pp. 310 - 315
Main Authors Eom, Bang Wool, Lee, Jun Ho, Lee, Jong Seok, Kim, Min Ju, Ryu, Keun Won, Choi, Il Ju, Cho, Soo-Jeong, Lee, Jong Yeul, Rhee, Jiyoung, Nam, Byung-Ho, Kim, Young-Woo
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2012
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background A tumor thrombus in the portal vein originating from gastric cancer is a rare condition. Little is known about the development of portal vein tumor thrombus (PVTT) and its effect on the survival of gastric cancer patients. Methods PVTT originating from gastric cancer was identified retrospectively with computed tomography in 51 patients, from January 2002 to June 2007. PVTT was classified by metastatic routes as follows: lymph node (LN), hepatic mass, and hematogenous type. The median survival from PVTT, and the factors affecting the survival of gastric cancer patients with PVTT were analyzed. Results The median survival of gastric cancer patients with PVTT (N = 51) was 5.4 months. The median survival was compared according to clinical characteristics, and multivariate analysis proved that female and hepatic mass type were independent risk factors for poor prognosis. The characteristics of the hepatic mass type were old age, higher proportion of tumors located in the upper‐third of the stomach, and liver metastasis, compared to the LN or the hematogeneous type. Conclusions PVTT originating from gastric cancer was a poor prognostic factor and the median survival from PVTT was different according to several clinical factors. J. Surg. Oncol. 2012; 105:310–315. © 2011 Wiley Periodicals, Inc.
Bibliography:istex:7DD0AAD967D7F1F766C653CCF721C076B4790677
ark:/67375/WNG-VRKMC6FZ-C
ArticleID:JSO22083
Korean National Cancer Center - No. 1010490
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.22083